Biography for Ryan McBride
Ryan McBride is an award-winning journalist who writes about the life sciences industry. Prior to joining FierceMarkets, he was a freelance journalist and served as a correspondent at Xconomy for more than two years. His stories have appeared in The Boston Globe, the Boston Business Journal, The Motley Fool, and many other publications. In recent years, he has also given guest lectures to graduate students at Boston University’s Center for Science & Medical Journalism. Earlier in his career, he held staff reporter positions at Mass High Tech, Providence Business News, and The Westerly Sun. Ryan enjoys spending time with his family and exploring mountains and beaches in New England. Follow Ryan on Twitter at @RyanMFierce or send him e-mail here.
Articles by Ryan McBride
With one likely blockbuster on the market in Eylea and at least three others in development, Regeneron Chief Scientific Officer Dr. George Yancopoulos has plenty to keep him busy for the next several years. Read the full feature >>
The agency has given the coveted status to the Lexington, MA-based biotech company's experimental treatment for use against early onset lysosomal acid lipase deficiency, an inherited disorder that typically kills infants within the first 6 month of life, according to the company.
Effector Therapeutics has rallied marquee investors for a sizable $45 million Series A financing, determined to use discoveries in protein translation to mine for new cancer drugs.
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
Sanofi can't shake the underproductive R&D site in Toulouse, France, without a fight from workers and French government officials. In the latest chapter of the ongoing feud, the Paris-based drug giant and a familiar critic in France's government show how far apart they stand on the fate of the research operation that brought the world the blood-thinner
Two more biotech outfits emerged this week as contenders to complete initial public offerings, highlighting the open season for the deals this year. Bluebird bio and PTC Therapeutics has mounted campaigns to go public with pipelines that target the molecular causes of rare genetic diseases.
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Before the massive ASCO meeting kicks off on May 31, the Swiss drug giant plans to unveil data from a late-stage study of its next-gen antibody GA101, which is heir to the throne occupied by the company and partner Biogen Idec's Rituxan.
Los Angeles-based biotech startup Kite Pharma has locked in $20 million in a private placement with its new investor Alta Partners and previous backers. By converting $15 million in previous promissory notes to stock, the company has increased the first-round financing to $35 million.